Factores predictores de actividad clínica en paciente con artritis reumatoide temprana en una cohorte colombiana

dc.contributorQuintana-Lopez, Gerardo
dc.creatorPrieto Rayo, Yised Natalia
dc.date.accessioned2021-08-27T21:24:09Z
dc.date.available2021-08-27T21:24:09Z
dc.date.created2021-08-27T21:24:09Z
dc.date.issued2021-08-26
dc.identifierhttps://repositorio.unal.edu.co/handle/unal/80045
dc.identifierUniversidad Nacional de Colombia
dc.identifierRepositorio Institucional Universidad Nacional de Colombia
dc.identifierhttps://repositorio.unal.edu.co/
dc.description.abstractMateriales y Métodos: El proyecto se realizó a partir de una cohorte histórica de la Clínica de Artritis Reumatoide de la fundación santa fe de Bogotá, seleccionando pacientes con inicio de los síntomas menores de 12 meses. Buscamos encontrar factores asociados a remisión sostenida a corto plazo definida como DAS28 VSG <2.6, DAS 28 PCR <2.6, SDAI <3.3 CDAI <2.8 en al menos dos ocasiones consecutivas donde el tiempo entre la primera y la última visita en la que la enfermedad estaba en remisión fue ≥ 6 meses o ≥ 24 meses remisión sostenida a largo plazo. Se realizó un análisis univariado y análisis multivariado de Regresión Logística para la selección de variables Resultados: 165 paciente fueron incluidos. Se logro remisión sostenida a corto plazo por DAS 28 VSG en 74% de los pacientes, remisión por DAS 28 PCR en el 50% de los pacientes, remisión sostenida a largo plazo DAS 28 VSG en 46% de los pacientes, DAS 28 PCR en 52% de los pacientes. Los predictores de remisión sostenida a corto plazo fueron Artritis reumatoide muy temprana (OR 2,6 CI 1.26-5.91; P=0.012), Consumo de alcohol (OR 3,86 CI 0.98-18.1 P=0.065), DAS 28 VSG_0 (OR 0.41 CI 0.26-0.62 P=<0.001), Antecedente familiar de AR (OR 0.42 CI 0.17-0.99 P=0.052) y los factores de remisión sostenida a largo plazo fueron el sexo masculino (OR 5.21; CI 1.98-14.9; P=0.001), y la duración de síntomas e inicio de FARME (OR 0.81 CI 0.66-0.99; P=0-046) Conclusiones: Las características demográficas de la cohorte fueron similares a las encontradas en cohortes previamente descritas, los factores que podrían predecir remisión sostenida a corto plazo con significancia estadística fueron el diagnóstico temprano de la enfermedad (VERA), el consumo de alcohol y la menor clinimetria por DAS28 VSG, al ingreso a la cohorte y los factores predictores de remisión sostenida a largo plazo fueron ser hombre y el inicio temprano de terapia.
dc.description.abstractRheumatoid arthritis is a chronic systemic disease, in which early diagnosis is essential in the prevention of unfavorable outcomes. Materials and methods: This project was elaborated from a historic cohort from the Clínica de Artritis Reumatoide, Fundación Santa Fe de Bogotá, selecting patients with an onset of symptoms lesser than 12 moths. We aim to find associated factors with a short term sustained remission defined by DAS28 VSG <2.6, DAS 28 PCR <2.6, SDAI <3.3 CDAI <2.8 in least in two consecutive locations in between the first and last medical visit, time in which the disease was on remission, ≥ 6 months defined as short term sustained remission or ≥ 24 moths defined as long term sustained remission. A univariate analysis was made, along with a multivariate logistic regression analysis to carry out the selection of the variables. Results: 165 patients were included in the study. Short term sustained remission by DAS 28 VSG was achieved in 74%of the patients, DAS 28 PCR in 50% of the patients, long term sustained remission by DAS 28 VSG in 46% of the patients and DAS 28 PCR in 52% of the patients. The predictors of short term sustained remission were Very Early Rheumatoid Arthritis OR 2,69; (OR 2,6 CI 1.26-5.91; P=0.012), alcohol consumption (OR 3,86 CI 0.98- 18.1 P=0.065), DAS 28 VSG_0 (OR 0.41 CI 0.26-0.62 P=<0.001), and family history of AR (OR 0.42 CI 0.17-0.99 P=0.052). The predictors for long term sustained remission were male gender (OR 5.21; CI 1.98-14.9; P=0.001), duration of the symptoms and the onset of FARME (OR 0.81 CI 0.66-0.99; P=0-046).
dc.languagespa
dc.publisherUniversidad Nacional de Colombia
dc.publisherBogotá - Medicina - Especialidad en Reumatología
dc.publisherDepartamento de Medicina Interna
dc.publisherFacultad de Medicina
dc.publisherBogotá, Colombia
dc.publisherUniversidad Nacional de Colombia - Sede Bogotá
dc.relation1. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis : pathological mechanisms and modern pharmacologic therapies. Bone Res [Internet]. 2018;(87). Available from: http://dx.doi.org/10.1038/s41413-018-0016-9
dc.relation2. Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM. Best Practice & Research Clinical Rheumatology Genetic and environmental risk factors for rheumatoid arthritis. Best Pract Res Clin Rheumatol [Internet]. 2017;1–16. Available from: http://dx.doi.org/10.1016/j.berh.2017.08.003
dc.relation3. Frisell T, Saevarsdottir S, Askling J. Family history of rheumatoid arthritis: an old concept with new developments. Nat Rev Rheumatol 2016;12(6):335e43
dc.relation4. Carmona L, Ot T. Best Practice & Research Clinical Rheumatology The epidemiology of established rheumatoid arthritis. 2019;(xxxx).
dc.relation5. Tobón GJ, Youinou P, Saraux A. The environment , geo-epidemiology , and autoimmune disease : Rheumatoid arthritis. J Autoimmun [Internet]. 2010;35(1):10–4. Available from: http://dx.doi.org/10.1016/j.jaut.2009.12.009
dc.relation6. Fernández-ávila DG, Rincón-ria DN, Gutiérrez JM. Investigación original Prevalencia de la artritis reumatoide en Colombia según información del Sistema Integral de Información de la Protección Social. 2020;6(2):83–7.
dc.relation7. Machado-alba JE, Felipe A, Alejandro D, Morales M. The epidemiology of rheumatoid arthritis in a cohort of Colombian patients. Rev Colomb Reumatol [Internet]. 2015;22(3):148–52. Available from: http://dx.doi.org/10.1016/j.rcreu.2015.05.006
dc.relation8. Díaz-rojas JA, Dávila-ramírez FA, Quintana-lópez G, Aristizábal-gutiérrez F. Investigación original Prevalencia de artritis reumatoide en Colombia : una aproximación basada en la carga de la enfermedad durante el a no. Rev Colomb Reumatol [Internet]. 2016;(x x):2–7. Available from: http://dx.doi.org/10.1016/j.rcreu.2015.12.004
dc.relation9. Silman AJ, Hennessy E, Ollier B (1992) Incidence of rheumatoid arthritis in a genetically predisposed population. Br J Rheumatol31(6):365–368
dc.relation10. Adi J. Insights of rheumatoid arthritis risk factors and associations. J Transl Autoimmun [Internet]. 2019;2(March):100012. Available from: https://doi.org/10.1016/j.jtauto.2019.100012
dc.relation11. Alfredsson L, Karlson EW. Environmental influences on risk for rheumatoid arthritis Katherine P. 2009
dc.relation12. Costenbader KH, Feskanich D, Mandl LA, Karlson EW. Smoking Intensity , Duration , and Cessation , and the Risk of Rheumatoid Arthritis in Women. 2006;503–11.
dc.relation13. Alfredsson L, Karlson EW. Environmental influences on risk for rheumatoid arthritis Katherine P. 2009
dc.relation14. Azizov V, Dietel K, Steffen F, Dürholz K, Meidenbauer J, Lucas S, et al. and the development of autoimmune arthritis. Nat Commun [Internet]. (2020). Available from: http://dx.doi.org/10.1038/s41467-020-15855-z
dc.relation15. Manuscript A. NIH Public Access. 2013;45(2):170–9.
dc.relation16. Yarwood A, Huizinga TWJ, Worthington J. RA : from risk factors and pathogenesis to prevention The genetics of rheumatoid arthritis : risk and protection in different stages of the evolution of RA. 2016;(September 2014):199–209.
dc.relation17. Viatte S. Genetics of rheumatoid arthritis susceptibility, severity, and treatment response. 2017;395–408.
dc.relation18. Castro-santos P, Díaz-pe R. Review article Genetics of rheumatoid arthritis: a new boost is. 2015;6(2):171–7.
dc.relation19. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. Arthritis & Rheumatism. 2010;62(9):2569–81.
dc.relation20. Zambon A, Caporali R, Sakellariou G, Scire CA, Montecucco C. Performance of the 2010 Classification Criteria for Rheumatoid Arthritis : A Systematic Literature Review and a Meta-Analysis. 2013;8(2):1–10.
dc.relation21. Jeffery RC. Clinical features of rheumatoid arthritis. Medicine (Baltimore) [Internet]. 2014;42(5):231–6. Available from: http://dx.doi.org/10.1016/j.mpmed.2014.02.011
dc.relation22. Grassi W, Angelis R De, Lamanna G, Cervini C. The clinical features of rheumatoid arthritis. 1998;27:18–24.
dc.relation23. Lee DM, Weinblatt ME. Rheumatoid arthritis. 2001;358:903–11.
dc.relation24. Nell V, Stamm T, Aletaha D, Smolen JS. Early rheumatoid arthritis. :282–8
dc.relation. 25. Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-gracia JM, et al. 2016 update of the EUL AR recommendations for the management of early arthritis. 2017;948–59.
dc.relation26. Cannella AC, Dell JRO. Early Rheumatoid Arthritis Pitfalls in Diagnosis and Review of Recent Clinical Trials. 2006;66(10):1319–37.
dc.relation27. Kmiliauskis R, Gomes S, Linhares AC De, Lersch LS. Prevalence and factors associated with diagnosis of early rheumatoid arthritis in the south of Brazil. 2018;8:1–10.
dc.relation28. Ridgley LA, Anderson AE, Pratt AG. What are the dominant cytokines in early rheumatoid arthritis ? 2018;0.
dc.relation29. Wabe N, Wojciechowski J, Wechalekar MD, Cleland LG, Mcwilliams L, Lee A, et al. Disease activity trajectories in early rheumatoid arthritis following intensive DMARD therapy over 3 years : association with persistence to therapy. 2017;
dc.relation30. Odegard S, Finset A, Kvien TK, Mowinckel P, Uhlig T. Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7- year study from the Oslo RA register. Scand J Rheumatol 2005;6:441–7.
dc.relation31. Twigg S, Hensor EMA, Emery P, Tennant A, Morgan AW, Twigg S, et al. Patient-reported Outcomes as Predictors of Change in Disease Activity and Disability in Early Rheumatoid Arthritis : Results from the Yorkshire Early Arthritis Register Patient-reported Outcomes as Predictors of Change in Disease Activity and Disability in Early Rheumatoid Arthritis : Results from the Yorkshire Early Arthritis Register. 2017
dc.relation32. Forslind K, Hafstro I. Sex : a major predictor of remission in early rheumatoid. 2007;46–53.
dc.relation33. Bird P, Nicholls D, Barrett R, Jager JDE, Griffiths H, Roberts L, et al. Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis : the PREDICT study. 2017;1–9.
dc.relation34. Favalli EG, Biggioggero M, Crotti C, Becciolini A, Raimondo MG, Meroni PL. Sex and Management of Rheumatoid Arthritis. 2018
dc.relation35. Gremese E, Salaf F, Bosello SL, Ciapetti A, Bobbio-pallavicini F, Caporali R, et al. Very early rheumatoid arthritis as a predictor of remission : a multicentre real life prospective study. 2013;(July 2009):858–62.
dc.relation36. Bosello S, Fedele AL, Peluso G, Gremese E, Tolusso B. Very early rheumatoid arthritis is the major predictor of major outcomes : clinical ACR remission and radiographic non-progression. 2011;1292–5.
dc.relation37. Sundlisæter NP, Olsen IC, Aga A, Heijde V Der, Kvien TK, Hammer B, et al. Original article Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol. 2018;(July):1–10.
dc.relation38. Maxwell JR, Gowers IR, Moore DJ, Wilson AG. Original article Alcohol consumption is inversely associated with risk and severity of rheumatoid arthritis. 2010;(July):2140–6.
dc.relation39. Pedersen M, Jacobsen S, Klarlund M, Pedersen B V, Wiik A, Wohlfahrt J, et al. Research article Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. 2006;8(4).
dc.relation40. Hazes W, Dijkmans AC, Vandenbroucke P. Lifestyle and the risk of rheumatoid arthritis : cigarette smoking and alcohol consumption. 1990;980–2.
dc.relation41. Sugiyama D, Nishimura K, Tamaki K, Tsuji G, Nakazawa T, Morinobu A, et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2010; 69(1):70–81. [PubMed: 19174392]
dc.relation42. Sparks JA, Chang S, Nguyen UDT, Costenbader H, Zhang Y, Choi HK. HHS Public Access. 2019;70(1):19–29.
dc.relation43. Rydell E, Forslind K, Nilsson J-åke, Jacobsson LTH, Turesson C. Smoking , body mass index , disease activity , and the risk of rapid radiographic progression in patients with early rheumatoid arthritis. 2018;1–11.
dc.relation44. Saevarsdottir S, Rezaei H, Geborek P, Petersson I, Albertsson K, Forslind K, et al. Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis : results from the SWEFOT trial. 2015;1509–14.
dc.relation45. Archer R, Hock E, Hamilton J, Stevens J, Essat M, Poku E, et al. Health technology assessment. 2018;22(66).
dc.relation46. Zeben D Van, Hazes JMW, Zwinderman AH, Cats A. Clinical significance of rheumatoid factors in early rheumatoid arthritis : results of a follow up study. 1992;1029–35.
dc.relation47. Eberhardt K, Hafstro I. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). 2004;1090–5.
dc.relation48. Report E. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). 2004;1085–9.
dc.relation49. of low titer anti-nuclear antibodies in early rheumatoid arthritis : implications on the presentation and long-term course of the disease. 2001;43–7.
dc.relation50. Ishikawa Y, Hashimoto M, Ito H, Tanaka M, Yukawa N, Fujii T, et al. Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis response to biological disease-modifying anti-rheumatic drugs in patients. Semin Arthritis Rheum [Internet]. 2019;(February). Available from: https://doi.org/10.1016/j.semarthrit.2019.02.003
dc.relation51. High Body Mass Index With Decreased Treatment Response to Combination Therapy in Recent-Onset Rheumatoid Arthritis. 2013;65(8):1235–42.
dc.relation52. he Impact of Obesity on Remission and Disease Activity in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis, DOI 10.1002/acr.22932
dc.relation53. Boire G, Mph JEP, Hitchon C. No Title. :0–3. Overweight and Obesity Reduce the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort Study. 2016.
dc.relation54. Activity D, Damage J. HHS Public Access. 2016;67(7):940–6.
dc.relation55. Yang G, Bykerk VP, Boire G, Hitchon CA, Thorne JC, Tin D, et al. Does Socioeconomic Status Affect Outcomes in Early Inflammatory Arthritis? Data from a Canadian Multisite Suspected Rheumatoid Arthritis Inception Cohort. 2015;
dc.relation56. Yang D, Huang J, Chiou J, Wei JC. Analysis of Socioeconomic Status in the Patients with Rheumatoid Arthritis. 2018;
dc.relation57. Massardo L, Pons-estel BA, Wojdyla D, Cardiel MH, Sacnun NP, Soriano ER, et al. Early Rheumatoid Arthritis in Latin America: Low Socioeconomic Status Related to High Disease Activity at Baseline. 2012;64(8):1135–43.
dc.relation58. Smolen JS, Heijde MFM Van Der, Clair EWS, Emery P, Bathon JM, Keystone E, et al. Predictors of Joint Damage in Patients With Early Rheumatoid Arthritis Treated With High-Dose Methotrexate With or Without Concomitant Infliximab Results From the ASPIRE Trial. 2006;54(3):702–10.
dc.relation59. Salaffi F. R eview Clinical disease activity assessments in rheumatoid arthritis R eview. 2013;347–60.
dc.relation60. Prevoo MLL, Hof MAVANT, Kuper HH, Leeuwen MAVAN. MODIFIED DISEASE ACTIVITY SCORES THAT INCLUDE TWENTY-EIGHT-JOINT COUNTS Development and Validation in a Prospective Longitudinal Study of Patients with Rheumatoid Arthritis. 1995;38(1):44–8.
dc.relation61. Singh H, Kumar H, Handa R, Talapatra P, Ray S, Gupta V. Use of Clinical Disease Activity Index Score for Assessment of Disease Activity in Rheumatoid Arthritis Patients : An Indian Experience. 2011;2011.
dc.relation62. Assessment MH, Health I, Questionnaire A. Measures of Functional Status and Quality of Life in Rheumatoid Arthritis. 2011;63(November):4–13.
dc.relation63. Uhlig T, Haavardsholm EA, Kvien TK. Comparison of the Health Assessment Questionnaire ( HAQ ) and the modified HAQ ( MHAQ ) in patients with rheumatoid arthritis. 2006;(454):454–8
dc.relation64. Subramanian S. Remission in Rheumatoid arthritis: a reality in 2017. 2017;(January).
dc.relation65. Felson D. (2012). Defining remission in rheumatoid arthritis. Annals of the rheumatic diseases, 71 Suppl 2(0 2), i86–i88. https://doi.org/10.1136/annrheumdis
dc.relation66. Ajeganova S, Huizinga T. Sustained remission in rheumatoid arthritis : latest evidence and clinical considerations. 2017;249–62.
dc.relation67. Id YS, Yoshida K, Prince FHM, Frits ML, Cho K, Choe J, et al. Prevalence and predictors for sustained remission in rheumatoid arthritis. 2019;92:1–11.
dc.relation68. Yilmaz-oner S, Gazel U, Can M, Atagunduz P, Direskeneli H, Inanc N. Predictors and the optimal duration of sustained remission in rheumatoid arthritis. 2019;
dc.relation69. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2016 update. 2017;1–18.
dc.relation70. Tanaka Y, Smolen JS, Jones H, Szumski A, Marshall L, Emery P. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis. 2019; 4:1–16.
dc.relation71. Peláez I, Cuervo F, Angarita I, Londo J, Giraldo R, Camilo J, et al. Prevalencia de la enfermedad reumática en Colombia, según estrategia COPCORD-Asociación prevalencia de enfermedad reumática en población colombiana mayor de 18 a nos. 2018;5(4):245–56.
dc.relation72. Montoya N, Rosselli D. Costos directos del tratamiento de pacientes con artritis reumatoide en Medellín, Colombia. 2011; 18:26–33.
dc.relation73. Kiely P, Williams R, Walsh D, Young A, Arthritis R, Eran N. Contemporary patterns of care and disease activity outcome in early rheumatoid arthritis : the ERAN cohort. 2009;(November 2008):57–60.
dc.relation74. Brian Tom , Characterization of disease course and remission in early seropositive rheumatoid arthritis: Results from the TACERA longitudinal cohort study RA-MAP Consortium, medRxiv 2020.03.08.20028142
dc.relation75. .Combe B. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. 2004;675–80.
dc.relation76. 1Boire G, Mph JEP, Hitchon C. 1. Overweight and Obesity Reduce the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort Study
dc.relation77. Thorne C, Bykerk V, Lazovskis J, Breton C, Hospital R. The Journal of Rheumatology Early Management of Newly Diagnosed Rheumatoid Arthritis by Canadian Rheumatologists : A National , Multicenter , Retrospective Cohort. 2011;(April 2016).
dc.relation78. Boman A, Brink M, Lundquist A, Hansson M, Mathsson-alm L, Rönnelid J, et al. Antibodies against citrullinated peptides are associated with clinical and radiological outcomes in patients with early rheumatoid arthritis : a prospective longitudinal inception cohort study. 2019;1–10.
dc.relation79. Rydell E, Forslind K, Nilsson J-åke, Karlsson M, Åkesson KE, Jacobsson LTH, et al. Predictors of radiographic erosion and joint space narrowing progression in patients with early rheumatoid arthritis : a cohort study. 2021;1–13.
dc.relation80. Hmamouchi I, Combe B, Fautrel B, Rincheval N, Lukas C. validated indices in the early arthritis “ESPOIR ” cohort. Jt Bone Spine [Internet]. 2014; Available from: http://dx.doi.org/10.1016/j.jbspin.2014.02.007
dc.relation81. Lu B, Rho YH, Cui J, Christine K. Associations of Smoking and Alcohol Consumption With Disease Activity and Functional Status in Rheumatoid Arthritis2015;41(1):24–30.
dc.relation82. Paulus HE, Wiesner J, Bulpitt KENJ, Patnaik M, Law J, Park GS, et al. Autoantibodies in Early Seropositive Rheumatoid Arthritis , Before and During Disease Modifying Antirheumatic Drug Treatment. 2002;2513–20.
dc.relation83. Barahona-correa JE, Flórez-suárez J. Does healthcare regime affiliation influence the clinical outcomes of patients with rheumatoid arthritis ? 2020;
dc.relation84. Ma MHY, Ibrahim F, Walker D, Hassell A, Choy EH, Kiely PDW, et al. Remission in Early Rheumatoid Arthritis : Predicting Treatment Response. 2012;39(3)
dc.relation. 85. Ma MHY, Defranoux N, Li W, Sasso EH, Ibrahim F, Scott DL, et al. A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis. 2020;1–12.
dc.relation86. Källmark H, Einarsson JT, Nilsson Å, Olofsson T, Saxne T, Geborek P. Sustained Remission in Patients With Rheumatoid Arthritis Receiving Triple Therapy Compared to Biologic Therapy : A Swedish Nationwide Register Study. 2021;73(7):1135–44.
dc.relation87. Turk ,Kieran Murray, Yousef Alammari,1 Aine Gorman,1 Francis Young,1 Phil Gallagher, The effects of alcohol consumption and its associations with disease activity among 979 patients with inflammatory arthritis _ Enhanced Reader.pdf.
dc.relation88. Nissen MJ, Gabay C, Scherer A, Finckh A, Clinical S. The Effect of Alcohol on Radiographic Progression in Rheumatoid Arthritis. 2010;62(5):1265–72.
dc.relation89. Monteagudo-sa I, Kupper H. Clinical Remission and / or Minimal Disease Activity in Patients Receiving Adalimumab Treatment in a Multinational , Open-Label , Twelve-Week Study. 2008;59(1):32–41.
dc.relation90. Frisell T, Saevarsdottir S, Askling J. Does a family history of RA in fl uence the clinical presentation and treatment response in RA ? 2015;1–6.
dc.relation91. Radstake TRDJ, Barrera P, Albers JMC, Swinkels HL, Putte LBA Van De, Riel PLCM Van. Familial vs sporadic rheumatoid arthritis ( RA ). A prospective study in an early RA inception cohort. 2000;267–73.
dc.relation92. Jawaheer D, Messing S, Reed G, Ranganath VK, Kremer JM, Louie JS, et al. Significance of Sex in Achieving Sustained Remission in the Consortium of Rheumatology Researchers of North America Cohort of Rheumatoid Arthritis Patients. 2012;64(12):1811–8.
dc.relation93. Jayakumar K, Norton S, Dixey J, James D, Gough A, Williams P, et al. Original article Sustained clinical remission in rheumatoid arthritis : prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDS. 2012;(November 2011):169–75.
dc.relation94. Nell VPK, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. 2004;43(7):906–14.
dc.relation95. Anderson JJ, Wells G, Verhoeven AC, Felson DT. FACTORS PREDICTING RESPONSE TO TREATMENT IN RHEUMATOID ARTHRITIS The Importance of Disease Duration. 2000;43(1):22–9.
dc.relation96. Ruiz-Esquide, V. Smoking Impact on Radiographic Progression in An Early Rheumatoid Arthritis Cohort, 2011
dc.relation97. Saevarsdottir S, Wedre S, Seddighzadeh M, Bengtsson C, Wesley A, Lindblad S, et al. Patients With Early Rheumatoid Arthritis Who Smoke Are Less Likely to Respond to Treatment With Methotrexate and Tumor Necrosis Factor Inhibitors Observations From the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register Cohorts. 2011;63(1):26–36.
dc.relation98. Hua C, Buttgereit F, Combe B. Glucocorticoids in rheumatoid arthritis : current status and future studies. 2020;1–9.
dc.relation99. Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis. 2009;68(7):1094–1099.
dc.rightsAtribución-NoComercial-SinDerivadas 4.0 Internacional
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleFactores predictores de actividad clínica en paciente con artritis reumatoide temprana en una cohorte colombiana
dc.typeTrabajo de grado - Especialidad Médica


Este ítem pertenece a la siguiente institución